Armas Pharmaceuticals https://armaspharmaceuticals.com Tue, 08 Apr 2025 13:58:46 +0000 en-US hourly 1 https://armaspharmaceuticals.com/wp-content/uploads/ARMAS-icon-RGB-150x150.png Armas Pharmaceuticals https://armaspharmaceuticals.com 32 32 Armas Pharmaceuticals Announces the Reintroduction of Lidocaine Jelly 2% 30mL to the U.S. Market https://armaspharmaceuticals.com/armas-pharmaceuticals-announces-the-reintroduction-of-lidocaine-jelly-2-30ml-to-the-u-s-market/ Tue, 08 Apr 2025 13:58:45 +0000 https://armaspharmaceuticals.com/?p=1385

FREEHOLD, N.J., March 27, 2025 /PRNewswire/ — Armas Pharmaceuticals, a leading provider of high-quality pharmaceutical products, is pleased to announce the reintroduction of Lidocaine Jelly 2% 30mL to the U.S. market. This key product has been unavailable for more than two years, and its return underscores Armas’ commitment to providing critical medications with a focus on consistent supply and sustainability.

Lidocaine Jelly 2% is a topical anesthetic used in various medical applications, including urological and endoscopic procedures, to provide localized pain relief. Its reintroduction is expected to address a significant gap in the market and meet the needs of healthcare providers nationwide.

“Our mission at Armas Pharmaceuticals is to ensure that essential medications remain consistently available to the healthcare community,” said Joe Niemi, President & CEO of Armas Pharmaceuticals. “The return of Lidocaine Jelly 2% 30mL represents our ongoing commitment to supply chain sustainability and our ability to respond to critical product needs in the market. We will continue to expand our portfolio with a focus on reliability, quality, and patient care.”

Armas Pharmaceuticals continues to strengthen its presence in the pharmaceutical industry by offering a robust and growing portfolio of high-quality products. With a steadfast commitment to innovation and supply chain security, the company remains dedicated to addressing critical healthcare needs in the U.S. market.
For more information on Lidocaine Jelly 2% 30mL and other Armas Pharmaceuticals products, please visit www.armaspharma.com.

About Armas Pharmaceuticals
Armas Pharmaceuticals is a leading specialty pharmaceutical company committed to providing high-quality, accessible, and sustainable medications to the U.S. market. With a diverse portfolio spanning multiple therapeutic areas, Armas focuses on ensuring the consistent availability of essential medicines for healthcare providers and patients.

Contact:
Jenifer Arabia
Vice President, Marketing and Operations
Armas Pharmaceuticals
Email: Jarabia@armaspharma.com

]]> Armas Pharmaceuticals and Steriscience Enter Strategic Partnership to Commercialize Products for the U.S. Market https://armaspharmaceuticals.com/armas-pharmaceuticals-and-steriscience-enter-strategic-partnership-to-commercialize-products-for-the-u-s-market/ https://armaspharmaceuticals.com/armas-pharmaceuticals-and-steriscience-enter-strategic-partnership-to-commercialize-products-for-the-u-s-market/#respond Thu, 17 Mar 2022 12:07:00 +0000 https://armaspharmaceuticals.com/?p=85

Armas Pharmaceuticals, Inc. and Steriscience have today announced an exclusive partnership for the distribution and supply of products for the U.S. market. In the first full year of collaboration, Steriscience intends to launch up to eight products through Armas Pharmaceuticals with the first launches in the U.S. market commencing in Q2 2022. The market size of these initial launches generates approximately $431M, according to IQVIA data.

“We are excited for Armas to begin our strategics partnership with Steriscience. In addition to the planned launches, our two teams will be working closely to identify areas of product needs based on feedback from our customers. The initial product launches will address common product availability issues.” John Niemi, President & CEO, Armas Pharmaceuticals, Inc.

Neeraj Sharma, CEO, Steriscience, stated: “We are pleased to collaborate with Armas Pharmaceuticals for distribution and supply of our products in the U.S. and to provide hospitals and patients with an increased access to critical injectable medicines. This partnership is a step towards solving supply chain constraints in important life-saving antibiotics, anesthetics, and others. Armas Pharmaceuticals industry expertise and strong nationwide distribution network will help us deliver our products to our end user customers.”

About Armas Pharmaceuticals, Inc.

Armas Pharmaceuticals is a multi-source pharmaceutical company delivering an ever-growing portfolio of high-quality products that provide convenience, affordability, and consistency. Through the development of strong partnerships and industry relationships, Armas Pharmaceuticals maintains this pipeline of products with customer and patient satisfaction in mind. Headquartered in Freehold, New Jersey, Armas Pharmaceuticals is always open to new partnership opportunities and ways to offer our customers the highest quality products at affordable costs. For more information, please visit ArmasPharmaceuticals.com.

About Steriscience

Headquartered in Bengaluru, India, Steriscience is a privately held injectables company building a global presence across USA, EU and other markets with a focus on solving for the needs of healthcare professionals and patients. Steriscience is developing value-added sterile injectable that bridge the gap for healthcare workers by improving hospital workflows, increasing efficiencies, and ensuring reliability of medication to patients worldwide. With four world class manufacturing facilities located across India and Europe and a state-of-the-art R&D facility in Bengaluru, Steriscience is well positioned to be a strong injectables player.

Contact:
Jenifer Arabia
732-637-1717

]]> https://armaspharmaceuticals.com/armas-pharmaceuticals-and-steriscience-enter-strategic-partnership-to-commercialize-products-for-the-u-s-market/feed/ 0 Armas Pharmaceuticals Adds Four Generic Injectables As First Launches of 2020 https://armaspharmaceuticals.com/armas-pharmaceuticals-adds-four-generic-injectables-as-first-launches-of-2020/ https://armaspharmaceuticals.com/armas-pharmaceuticals-adds-four-generic-injectables-as-first-launches-of-2020/#respond Mon, 20 Jan 2020 11:58:10 +0000 https://armaspharmaceuticals.com/?p=78

Armas Pharmaceuticals Inc. (Armas), has begun the new year with launches of four generic injectables: Caffeine Citrate, Docetaxel, Gemcitabine and Verapamil HCI. These products are now a part of Armas’ consistently growing product line, bringing their portfolio count to eleven. The following are sizes available on each of the new products:

Caffeine Citrate Injection (the generic equivalent of Hikma’s, CAFCIT®), available in 60mg/3mL; has an approximate market size of $4M, annually.

Docetaxel Injection (the generic equivalent of Sanofi’s, Taxotere®), available in 20mg/1mL, 80mg/4mL and 160mg/8mL; has an approximate market size of $45M, annually.

Gemcitabine Injection (the generic equivalent of Eli Lilly’s, Gemzar®), available in 200mg/5.26mL, 1G/26.3mL and 2G/52.6mL; has an approximate market size of $25M, annually.

Verapamil HCI Injection (the generic equivalent of Pfizer’s, Calan®), available in 5mg/2mL and 10mg/4mL; has an approximate market size of $31M, annually.

“Building off the incredible success Armas saw in our first full year, we are excited to be adding these items to our growing product line,” said Joe Niemi, Chief Operating Officer, Armas Pharmaceuticals. “From the start, Armas’ mission was to bring affordability to healthcare and we continue to work towards that goal by partnering with our customers and bringing down the overall cost to the patient.”

About Armas Pharmaceuticals, Inc.

Armas Pharmaceuticals is a generic pharmaceutical company delivering an ever-growing portfolio of high-quality products that provide convenience, affordability and consistency. Through the development of strong partnerships and industry relationships, Armas maintains this pipeline of products with customer and patient satisfaction in mind. Headquartered in Manalapan, New Jersey, Armas Pharmaceuticals is always open to new partnership opportunities and ways to offer our customers the best products at affordable prices. For more information, please visit ArmasPharmaceuticals.com.

Contact:
Jenifer Arabia, Director, Sales & Marketing
Armas Pharmaceuticals
732-637-1717

]]> https://armaspharmaceuticals.com/armas-pharmaceuticals-adds-four-generic-injectables-as-first-launches-of-2020/feed/ 0 Armas Pharmaceuticals Announces Launch of Oncology Generic Erlotinib https://armaspharmaceuticals.com/armas-pharmaceuticals-announces-launch-of-oncology-generic-erlotinib/ https://armaspharmaceuticals.com/armas-pharmaceuticals-announces-launch-of-oncology-generic-erlotinib/#respond Wed, 13 Nov 2019 11:55:18 +0000 https://armaspharmaceuticals.com/?p=73

Armas Pharmaceuticals Inc. (Armas) is announcing the launch of generic Tarceva® (a trademark of Genentech USA, Inc) Tablets. Erlotinib is now available in 25mg, 100mg and 150mg strengths. This is Armas’ third oral solid to be added to their oncology portfolio.

“I am excited to announce our 6th product launch of 2019 and 7th overall. As evidenced by our rapidly growing product portfolio, I could not be more pleased with the efforts put forth by the Armas team, while still keeping our core values at the center of it all,” says John Niemi, President and CEO, of Armas Pharmaceuticals.

Erlotinib is used as a targeted therapy, indicated for patients with metastatic non-small cell lung cancer. The generated sales for Erlotinib are approximately $150 million annually, according to sales data.

About Armas Pharmaceuticals Inc.

Armas Pharmaceuticals is a generic pharmaceutical company delivering an ever-growing portfolio of high-quality products that provide convenience, affordability and consistency. Through the development of strong partnerships and industry relationships, Armas maintains this pipeline of products with customer and patient satisfaction in mind. Headquartered in Manalapan, New Jersey, Armas Pharmaceuticals is always open to new partnership opportunities and ways to offer our customers the best products at affordable prices.

Media Contact:
Jenifer Arabia
732-637-1717

]]> https://armaspharmaceuticals.com/armas-pharmaceuticals-announces-launch-of-oncology-generic-erlotinib/feed/ 0 Armas and Micro Labs Announce Collaboration To Launch Generic Injectables to U.S. Market https://armaspharmaceuticals.com/armas-and-micro-labs-announce-collaboration-to-launch-generic-injectables-to-u-s-market/ https://armaspharmaceuticals.com/armas-and-micro-labs-announce-collaboration-to-launch-generic-injectables-to-u-s-market/#respond Tue, 28 May 2019 12:02:00 +0000 https://armaspharmaceuticals.com/?p=82

Armas Pharmaceuticals Inc. and Micro Labs USA, Inc. have announced today, the forming of a strategic collaboration to bring select multisource injectable products to the U.S. market. The first product, Diphenhydramine Injection 50mg/1mL, is slated to be launched in May. Diphenhydramine has been seen on the FDA Drug Shortage list since September of 2018. Additional product launches are set for the second quarter of 2019. The market size of these products total $100 million annually, according to IMS data.

“Armas Pharmaceuticals is excited to partner with Micro Labs as we look to expand our product line across multiple therapeutic classes,” said John Niemi, President and CEO of Armas. “Our first launch with Micro Labs, Diphenhydramine Injection 50mg/1mL, is a medicinal drug used widely in the healthcare space. It is our aim to make this product available at affordable pricing to patients in need of the same. This medication reinforces our ultimate goal to bring high quality, affordable drugs that are needed in the U.S. market.”

Ashok Jain, Director of Micro Labs USA, Inc. said, “Micro and Armas have been working together on various ideas and projects. We are proud to be associated with Armas and we truly value the rich experience and understanding of the US healthcare sector they bring to the partnership.”

About Armas Pharmaceuticals, Inc.

Armas Pharmaceuticals is a generic pharmaceutical company delivering an ever-growing portfolio of high quality products that provide convenience, affordability and consistency. Through the development of strong partnerships and industry relationships, Armas maintains this pipeline of products with customer and patient satisfaction in mind. Headquartered in Manalapan, New Jersey, Armas Pharmaceuticals is always open to new partnership opportunities and ways to offer our customers the best products at affordable prices. For more information please visit ArmasPharmaceuticals.com.

About Micro Labs USA, Inc.

Micro Labs, established in 1972, is today one of the leading Pharmaceutical companies in India. Micro Labs is an integrated Pharmaceutical Company having its presence in the entire value chain from Research & Development, Manufacturing and Marketing of both active ingredients and formulations. With a sharp focus on quality affordable medicines, Micro Labs USA markets its full range of oral, ophthalmic and injectable formulations on its own, as well as by forging strategic partnerships. Mr. Jain added that over the last four decades, Micro has been relentlessly pursuing its vision of serving healthcare needs in multiple countries and today building on its legacy of success, Micro enters a new chapter in the US through this partnership with Armas.

Contact:
John Niemi
888-831-2292

]]> https://armaspharmaceuticals.com/armas-and-micro-labs-announce-collaboration-to-launch-generic-injectables-to-u-s-market/feed/ 0